NCT05704634 2026-04-15A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.M.D. Anderson Cancer CenterPhase 1 Active not recruiting56 enrolled